The Research Foundation for Microbial Diseases of Osaka University (BIKEN Co., Ltd.)

Go to main text

Vaccines protect
our future.

Press Release
& Update

2024/03/28
Press Release: Marketing Authorization Application of Intranasal Influenza Vaccine (BK1304)
2024/03/15
Press Release: Launch of “GOBIK Aqueous Suspension Syringes”, Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine
2024/01/23
Press Release: Co-promotion of “GOBIK Aqueous Suspension Syringes”, Pertussis, Diphtheria, Tetanus, Inactivated Polio and Hib Combined Vaccine
2023/09/27
Press Release: VLPT Japan, Biken Foundation, Denka sign agreement to develop self-amplifying “replicon” RNA influenza vaccine

About Us

The BIKEN Group will Continue to Protect the Precious Lives around the World
through Excellent Vaccines.

In 2017, the Research Foundation of Osaka University, BIKEN Foundation, and BIKEN Corporation started a new chapter known as the “BIKEN Group.”We will combine our strengths and work for better public health both in Japan and the entire world.